What We Believe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It is not a matter of editorial opinion to say these words: Black Lives Matter.

The existence of systemic racism, social inequality, and health disparities is indisputable, and not a matter of bias or opinion. This is grounded in science and data.

Cancer does not discriminate. Our social infrastructure does.

The Cancer Letter strives to give you unbiased, balanced coverage grounded in standards of evidence-based medicine, the principles of peer review, disclosures, health equity, and social justice.

Our coverage since 1973 has adhered to this mission. But all of us must do more.

Diversity is fundamental to fair and balanced coverage, and to achieving health equity. As a news publication, we must amplify the voices of those who have been historically marginalized. This requires an ongoing, concerted effort in a world where the people who hold the keys to power are disproportionately white and male.

NCI should be commended for emphasizing Community Outreach and Engagement as a key criterion for the designation of cancer centers. However, as a logical next step, we must also examine diversity at the cancer centers.

Of the 71 directors of NCI-Designated Cancer Centers, the vast majority are white and male. One is African American. Nine are women.

What does the leadership pipeline look like? We don’t know. No robust data exist on the diversity among directors and deputy directors of NCI-designated cancer centers. These data should be generated, and made publicly available.

All of us—scientists, physicians, and journalists—have a role to play in bringing forward diverse viewpoints. It’s fair, it’s equitable, and it’s essential to good science.

“In my experience, our endemic institutional racism is, and has always been, a public health issue,” Robert Winn writes. “In fact—as a result of the COVID-19 disaster—we are all now finally recognizing that racism is a contributing factor to chronic diseases, including cancer.”

Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 
Alexandria Carolan
Alexandria Carolan
Reporter
Katie Goldberg
Director of Operations
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login